细菌去定植预防放射性皮炎:一项随机临床试验
这项2/3期随机临床试验在城市学术癌症中心纳入接受根治性放疗的乳腺癌或头颈癌患者,评估细菌去定植(BD)较标准护理降低急性放射性皮炎(ARD)严重程度的效果。结果显示BD组无人发生2级伴湿性脱屑(2-MD)及以上ARD,标准护理组有9例(23.7%)发生(P=.001),结论提示BD对ARD预防有效,尤其对乳腺癌患者。
要点
- BD组39例均未发生ARD 2-MD及以上,标准护理组38例中9例(23.7%)发生(P=.001)。
- 乳腺癌患者中BD组无人发生ARD≥2-MD,标准护理组8例(21.6%)发生(P=.002)。
- BD组平均ARD分级1.2(0.7)低于标准护理组1.6(0.8)(P=.02)。
核心结论
- 这项随机临床试验结果提示,细菌去定植对急性放射性皮炎预防有效,尤其对乳腺癌患者。
研究设计与样本
- 2/3期随机临床试验,2019年6月至2021年8月在城市学术癌症中心开展,研究者设盲。
- 纳入接受根治性放疗的乳腺癌或头颈癌患者,最终志愿者样本80例,完成放疗者77例。
- 77例完成放疗患者中39例随机分入细菌去定植组,38例随机分入标准护理组;平均(SD)年龄59.9(11.9)岁,75例(97.4%)为女性。
主要发现
- 在77例乳腺癌和头颈癌患者中,BD组39例无人发生ARD 2-MD及以上,标准护理组38例中9例(23.7%)发生(P=.001)。
- 在75例乳腺癌患者中,BD组无人发生ARD≥2-MD,标准护理组8例(21.6%)发生(P=.002)。
- BD组平均(SD)ARD分级1.2(0.7),低于标准护理组的1.6(0.8)(P=.02)。
- 39例BD患者中27例(69.2%)报告依从方案,仅1例(2.5%)出现与BD相关的不良事件(即瘙痒)。
关键数值与推荐
- 主要结局为发生2级及以上ARD,基于2级ARD临床变异性大,修订为伴湿性脱屑的2级ARD(2-MD)。
- 干预方案为放疗前5天每日两次鼻内莫匹罗星软膏和每日一次氯己定沐浴液,放疗期间每2周重复5天。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Evidence-based approaches for the prevention of acute radiation dermatitis (ARD) are limited, and additional strategies are necessary to optimize care. OBJECTIVE: To determine the efficacy of bacterial decolonization (BD) to reduce ARD severity compared with standard of care. DESIGN, SETTING, AND PARTICIPANTS: This phase 2/3 randomized clinical trial was conducted from June 2019 to August 2021 with investigator blinding at an urban academic cancer center and enrolled patients with breast cancer or head and neck cancer receiving radiation therapy (RT) with curative intent. Analysis was performed on January 7, 2022. INTERVENTIONS: Intranasal mupirocin ointment twice daily and chlorhexidine body cleanser once daily for 5 days prior to RT and repeated for 5 days every 2 weeks through RT. MAIN OUTCOMES AND MEASURES: The primary outcome as planned prior to data collection was the development of grade 2 or higher ARD. Based on wide clinical variability of grade 2 ARD, this was refined to grade 2 ARD with moist desquamation (grade 2-MD). RESULTS: Of 123 patients assessed for eligibility via convenience sampling, 3 were excluded, and 40 refused to participate, with 80 patients in our final volunteer sample. Of 77 patients with cancer (75 patients with breast cancer [97.4%] and 2 patients with head and neck cancer [2.6%]) who completed RT, 39 were randomly assigned BC, and 38 were randomly assigned standard of care; the mean (SD) age of the patients was 59.9 (11.9) years, and 75 (97.4%) were female. Most patients were Black (33.7% [n = 26]) or Hispanic (32.5% [n = 25]). Among patients with breast cancer and patients with head and neck cancer (N = 77), none of the 39 patients treated with BD and 9 of the 38 patients (23.7%) treated with standard of care developed ARD grade 2-MD or higher (P = .001). Similar results were observed among the 75 patients with breast cancer (ie, none treated with BD and 8 [21.6%] receiving standard of care developed ARD grade ≥2-MD; P = .002). The mean (SD) ARD grade was significantly lower for patients treated with BD (1.2 [0.7]) compared with patients receiving standard of care (1.6 [0.8]) (P = .02). Of the 39 patients randomly assigned to BD, 27 (69.2%) reported regimen adherence, and only 1 patient (2.5%) experienced an adverse event related to BD (ie, itch). CONCLUSIONS AND RELEVANCE: The results of this randomized clinical trial suggest that BD is effective for ARD prophylaxis, specifically for patients with breast cancer. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03883828.
引用
- Kost Y, Deutsch A, Mieczkowska K, et al. Bacterial Decolonization for Prevention of Radiation Dermatitis: A Randomized Clinical Trial. JAMA Oncol. 2023. PMID: 37140904. doi:10.1001/jamaoncol.2023.0444
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。